CardioExchange Archive

September 29th, 2014

The Implications of PARADIGM-HF for Clinical Practice

Clyde Yancy, MD and Mary Norine Walsh, MD

Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.

---

September 8th, 2014

Selections from Richard Lehman’s Literature Review: September 8th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the PARADIGM-HF trial, sham controls in medical-device trials, the efficacy of β blockers in patients with heart failure and atrial fibrillation, and more.

---

September 5th, 2014

Perspectives on PARADIGM-HF

CardioExchange Editors, Staff

The Editors present a distillation of reader comments on a popular post.

---

September 1st, 2014

Let’s Take a Close Look at PARADIGM-HF

Vinay Prasad, MD MPH

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.

---

August 30th, 2014

ESC.14 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from ESC.14. Check out our coverage of the conference here at CardioExchange and don’t forget to tell us what you think! News: PARADIGM-HF Establishes a New Paradigm for Heart Failure Treatment SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug Preliminary Outcomes Results For PCSK9 Inhibitor New Support For […]

---

August 30th, 2014

Will There Be a PARADIGM Shift in Treatment of Heart Failure?

John McMurray, MbChB MD and Milton Packer, MD

John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

---

August 28th, 2014

Predicting PARADIGM-HF, or What to Expect When You’re Expecting

Larry Husten, PHD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

---